Coherus Biosciences | CHRS - Operating Profit


Coherus Biosciences reported $-39.08M in Operating Profit for its fiscal quarter ending in December of 2025.





Operating Profit Change Date
AbbVie USD 4.73B 1.08B Mar/2026
Acadia Pharmaceuticals USD -4.62M 22.01M Mar/2026
Akebia Therapeutics USD -5.45M 9.4M Dec/2025
ALKERMES USD -48.28M 37.33M Mar/2026
Alnylam Pharmaceuticals USD 137.59M 108.19M Mar/2026
Amarin USD -2.26M 564K Dec/2025
Amgen USD 3.83B 130M Mar/2026
Baxter International USD 66M 280.2M Mar/2026
Biogen USD 514.3M 128.8M Mar/2026
BioMarin Pharmaceutical USD 129.65M 68.74M Mar/2026
Bristol-Myers Squibb USD 4.2B 562M Dec/2025
Coherus Biosciences USD -39.08M 3.65M Dec/2025
Eli Lilly USD 9.78B 792M Mar/2026
Fujifilm JPY 101.76B 11.79B Mar/2026
Gilead Sciences USD 2.68B 284M Mar/2026
Ironwood Pharmaceuticals USD 33.22M 7.58M Dec/2024
Merck USD -1.88B 8.12B Mar/2026
Myriad Genetics USD -3M 20.3M Dec/2025
Pacira USD 4.62M 1.43M Mar/2026
Perrigo USD 33.6M 50.8M Mar/2026
Pfizer USD 4.99B 340M Mar/2026
PTC Therapeutics USD 45.89M 127.51M Mar/2026
Regeneron Pharmaceuticals USD 744.8M 153.8M Mar/2026
Sarepta Therapeutics USD 358.43M 768.52M Mar/2026
Teva Pharmaceutical Industries USD 758M 271M Mar/2026
Vertex Pharmaceuticals USD 1.14B 124.5M Mar/2026
Xencor USD -77.86M 24.23M Mar/2026
Zoetis USD 865M 30M Mar/2026